AngioDynamics (NASDAQ:ANGO) Stock Bumped Up to Hold by Zacks Research

Zacks Research upgraded shares of AngioDynamics (NASDAQ:ANGO) from a strong sell rating to a hold rating in a report released on Monday,Zacks reports.

A number of other equities analysts have also weighed in on the stock. Canaccord Genuity Group increased their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. HC Wainwright upped their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

AngioDynamics Price Performance

Shares of ANGO opened at $14.42 on Monday. The firm has a market cap of $606.36 million, a PE ratio of -16.57 and a beta of 0.30. The stock’s fifty day moving average price is $15.47 and its two-hundred day moving average price is $13.08. AngioDynamics has a 1 year low of $9.39 and a 1 year high of $16.29.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The firm had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Sell-side analysts anticipate that AngioDynamics will post -0.25 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Warren Jr sold 23,370 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ANGO. BlackRock Inc. purchased a new position in shares of AngioDynamics during the 2nd quarter valued at $49,480,000. Armistice Capital LLC boosted its stake in AngioDynamics by 3.9% during the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock valued at $21,828,000 after buying an additional 64,000 shares during the period. Weber Capital Management LLC ADV purchased a new position in AngioDynamics during the second quarter worth about $17,649,392. Bastion Asset Management Inc. grew its position in AngioDynamics by 17.4% during the first quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after buying an additional 194,822 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in AngioDynamics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock worth $10,786,000 after acquiring an additional 32,476 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.